Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.

The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...

Learn more about whether Natera, Inc. or Vertex Pharmaceuticals Incorporated is a better investment based on AAII's A+ ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company with a market capitalization of $113.7 billion, is navigating a critical juncture as it seeks to expand its therapeutic reach and ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a global biotechnology company with a market capitalization of $119.1 billion known for its transformative cystic fibrosis (CF) treatments, finds itself at a ...

Vertex has built an empire in cystic fibrosis ... projecting an 8.2% jump in sales for 2025 as new products gain traction.

The FDA recently approved Vertex Pharmaceuticals Incorporated’s Journavx (suzetrigine), a first-in-class non-opioid ...

With the biotech company's stock already posting impressive gains of over 9% in early 2025, it's worth examining whether Vertex stock ... in sales for 2025 as new products gain traction.

Wall Street sees plenty of growth ahead, projecting an 8.2% jump in sales for 2025 as new products gain traction. The balance sheet tells an equally compelling story: Vertex has $11.2 billion in ...

Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® ...

The Food and Drug Administration has approved a first-of-its-kind non-opioid pain medication, providing a new option for ...